FR
Fredun Pharmaceuticals Ltd (FREDUN)
₹1,693.90
Mkt cap
₹2,570 Cr
P/E ratio
48.00
P/B
8.64
Div yield
0.02%
ROE
15.80%
ROCE
21.50%
EPS (TTM)
₹35.29
Book value
₹196
52W range
1,195–1,735
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products [1]
NSE FREDUNBSE 539730
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−2.37% from high₹1,694
₹1,195+41.73% from low₹1,735
Current
₹1,693.90
Prev close
₹1,708.00
Day
−0.83%
Price performance
1D
−1.52%
1W
+12.07%
1M
+20.92%
3M
+14.28%
6M
—
1Y
—
YTD
+14.92%
Financials
Revenue, profit & margin
P/E ratio
48.0×
FREDUN is 41% above the sector median of 34.0×
FREDUN48.0×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 | 87 | 118 | 79 | 107 | 103 | 167 | 120 | 145 | 161 | 213 | 228 | 268 | |
| YoY Sales growth | +17% | +12% | +48% | +27% | +31% | +18% | +42% | +52% | +35% | +57% | +27% | +90% | +84% | |
| Expenses | 72 | 76 | 107 | 68 | 93 | 89 | 150 | 103 | 123 | 135 | 184 | 195 | 225 | |
| Operating Profit | 10 | 11 | 11 | 10 | 14 | 13 | 17 | 17 | 22 | 26 | 29 | 33 | 43 | |
| OPM % | 12% | 12% | 9% | 13% | 13% | 13% | 10% | 14% | 15% | 16% | 14% | 14% | 16% | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 3 | 4 | 4 | 4 | 5 | 5 | 8 | 7 | 8 | 11 | 14 | 9 | 9 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 4 | |
| Profit before tax | 6 | 6 | 6 | 6 | 8 | 7 | 8 | 9 | 13 | 14 | 12 | 21 | 30 | |
| Tax % | 32% | 27% | 13% | 25% | 44% | 25% | 12% | 25% | 25% | 25% | 4% | 36% | 37% | |
| Net Profit | 4 | 4 | 5 | 4 | 4 | 5 | 7 | 7 | 10 | 10 | 11 | 13 | 19 | |
| EPS in Rs | 2.79 | 2.99 | 3.59 | 2.91 | 3.01 | 3.75 | 4.98 | 4.77 | 6.85 | 6.51 | 6.75 | 7.98 | 11.14 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202643.62%Promoter
Promoters43.62%0.95
FIIs0.69%0.37
DIIs3.43%0.49
Public52.25%0.80
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Fredun Pharma | ₹1,500.80 | 48.00 | 2,570 | 0.02% | 19 | +93.53% | 268 | +84.19% | 21.49% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts13
Credit ratings6
Announcements5
Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Dated 14.11.2026 14 Nov - Board noted the Monitoring Agency Report for quarter ended September 30, 2026.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 14 Nov - CARE report dated Nov. 13, 2026 flags 10-25% deviation in Rs 153.25 crore preferential issue proceeds.Statement Of Deviation Or Variation For The Quarter Ended September 30, 2026. 14 Nov - Fredun Pharmaceuticals reports no deviation in use of ₹128.78 crore preferential issue proceeds for quarter ended 30 September 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Nov - Intimation of Earnings Conference Call for the Quarter Q2 of FY27Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - Newspaper Advertisement of the Un-Audited Financial Results for Quarter and Half-Year Ended 30th September, 2026






